Correction to: Impact of boost sequence in concurrent chemo-radiotherapy on newly diagnosed IDH-wildtype glioblastoma multiforme

被引：0
|
作者：
Nalee Kim
Joongyo Lee
Do-Hyun Nam
Jung-Il Lee
Ho Jun Seol
Doo-Sik Kong
Jung Won Choi
Kyuha Chong
Won Jae Lee
Jong Hee Chang
Seok-Gu Kang
Ju Hyung Moon
Jaeho Cho
Do Hoon Lim
Hong In Yoon
机构：
[1] Sungkyunkwan University School of Medicine,Department of Radiation Oncology, Samsung Medical Center
[2] Yonsei University College of Medicine,Department of Radiation Oncology, Yonsei Cancer Center, Severance Hospital, Yonsei University Health System
[3] Sungkyunkwan University School of Medicine,Department of Neurosurgery, Brain Tumor Center, Samsung Medical Center
[4] Yonsei University College of Medicine,Department of Neurosurgery, Severance Hospital, Yonsei University Health System
[5] Yonsei University College of Medicine,Brain Tumor Center, Severance Hospital, Yonsei University Health System
[6] Yonsei University College of Medicine,Department of Radiation Oncology, Heavy Ion Therapy Research Institute, Yonsei Cancer Center, Yonsei University Health System
来源：
Journal of Neuro-Oncology | 2023年 / 165卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：269 / 269
相关论文
共 35 条
  • [21] Early platelet variation during concomitant chemo-radiotherapy predicts adjuvant temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma patients
    Fontanilles, Maxime
    Marguet, Florent
    Alexandru, Cristina
    Langlois, Olivier
    Veresezan, Ovidiu
    Gilard, Vianney
    David, Marion
    Laquerriere, Annie
    Hanzen, Chantal
    Tennevet, Isabelle
    Di Fiore, Frederic
    Clatot, Florian
    SUPPORTIVE CARE IN CANCER, 2019, 27 (02) : 477 - 484
  • [22] Early platelet variation during concomitant chemo-radiotherapy predicts adjuvant temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma patients
    Maxime Fontanilles
    Florent Marguet
    Cristina Alexandru
    Olivier Langlois
    Ovidiu Veresezan
    Vianney Gilard
    Marion David
    Annie Laquerriere
    Chantal Hanzen
    Isabelle Tennevet
    Frédéric Di Fiore
    Florian Clatot
    Supportive Care in Cancer, 2019, 27 : 477 - 484
  • [23] THE SIGNIFICANCE OF TERT PROMOTER MUTATIONS, TELOMERE LENGTH AND MGMT PROMOTER METHYLATION IN NEWLY DIAGNOSED AND RECURRENT IDH-WILDTYPE GLIOBLASTOMA (GBM): A LARGE MONO-INSTITUTIONAL STUDY
    Lombardi, Giuseppe
    Giunco, Silvia
    Cavallin, Francesco
    Angelini, Chiara
    Caccese, Mario
    Cerretti, Giulia
    De Bonis, Pasquale
    De Rossi, Anita
    Zagonel, Vittorina
    NEURO-ONCOLOGY, 2021, 23 : 15 - 15
  • [24] Early platelet variation during concomitant chemo-radiotherapy predicts adjuvant temozolomide-induced thrombocytopenia in newly-diagnosed glioblastoma
    Fontanilles, M.
    Clatot, F.
    Alexandru, C.
    Langlois, O.
    Veresezan, O.
    Marguet, F.
    David, M.
    Laquerriere, A.
    Hanzen, C.
    Bouilly, I. Tennevet
    Di Fiore, F.
    ANNALS OF ONCOLOGY, 2017, 28
  • [25] Hypofractionated radiotherapy with concurrent temozolomide chemotherapy in patients with newly diagnosed RPA class V glioblastoma multiforme: promising early results
    Ye, Jason C.
    Yondorf, Menachem
    Pannullo, Susan C.
    Boockvar, John A.
    Stieg, Philip E.
    Schwartz, Theodore H.
    Scheff, Ronald J.
    Parashar, Bhupesh
    Nori, Dattatreyudu
    Chao, K. S. Clifford
    Wernicke, A. Gabriella
    JOURNAL OF RADIATION ONCOLOGY, 2015, 4 (01) : 19 - 27
  • [26] PHASE II TRIAL OF HYPOFRACTIONATED INTENSITY-MODULATED RADIOTHERAPY WITH CONCURRENT AND ADJUVANT TEMOZOLOMIDE FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME
    Chen, Changhu
    Damek, Denise
    Gaspar, Laurie E.
    Ney, Douglas
    Waziri, Allen
    Lillehei, Kevin
    Kavanagh, Brian D.
    NEURO-ONCOLOGY, 2011, 13 : 128 - 128
  • [27] A Propensity-Matched Study to Evaluate PTEN and TP53 Mutations as Predictive Biomarkers of Survival in Newly Diagnosed IDH-Wildtype Glioblastoma after Tumor Treating Fields
    Cordova, J. S.
    Pan, P. C.
    Alnahhas, I.
    Kanyne, A.
    Huang, Y.
    Shi, W.
    Wang, T. J. C.
    Huang, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E69 - E69
  • [28] Randomized, placebo-controlled, phase II study of dasatinib with standard chemo-radiotherapy for newly diagnosed glioblastoma (GBM), NCCTG N0877 (Alliance)
    Laack, Nadia N.
    Galanis, Evanthia
    Anderson, S. Keith
    Leinweber, Clinton
    Buckner, Jan C.
    Giannini, Caterina
    Geoffroy, Francois J.
    Johnson, Derek Richard
    Lesser, Glenn Jay
    Jaeckle, Kurt A.
    Sarkaria, Jann Nagina
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] REGORAFENIB IN COMBINATION WITH TEMOZOLOMIDE WITH OR WITHOUT RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED MGMT-METHYLATED, IDH WILDTYPE GLIOBLASTOMA: A PHASE I DOSE-FINDING STUDY (REGOMA-2)
    Padovan, Marta
    De Salvo, Gian Luca
    D'Avolio, Antonio
    Caccese, Mario
    Zagonel, Vittorina
    Lombardi, Giuseppe
    NEURO-ONCOLOGY, 2022, 24 : 73 - 73
  • [30] A RANDOMIZED TRIAL OF INTERSTITIAL RADIOTHERAPY (IRT) BOOST FOR THE TREATMENT OF NEWLY-DIAGNOSED MALIGNANT GLIOMA (GLIOBLASTOMA-MULTIFORME, ANAPLASTIC ASTROCYTOMA, ANAPLASTIC OLIGODENDROGLIOMA, MALIGNANT MIXED GLIOMA) - BTCG STUDY-8701
    SHAPRIO, WR
    GREEN, S
    BURGER, P
    SELKER, R
    VANGILDER, J
    SARIS, S
    MALKIN, M
    MEALEY, J
    NEAL, J
    ROBERTSON, J
    OLSON, J
    NEUROLOGY, 1994, 44 (04) : A263 - A263
1234